Related Experiment Video
Updated: Jun 20, 2026

Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
Published on: March 26, 2019
Progressive multifocal leukoencephalopathy after natalizumab monotherapy
Hans Lindå1, Anders von Heijne, Eugene O Major
1Neurology Unit, Division of Internal Medicine, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden. hans.linda@ki.se
Progressive multifocal leukoencephalopathy (PML) developed in a multiple sclerosis patient on natalizumab. Early diagnosis using sensitive PCR and plasma exchange improved outcomes.
Area of Science:
- Neuroimmunology
- Viral Pathogenesis
Background:
- Natalizumab is an effective treatment for multiple sclerosis.
- JC virus reactivation can cause progressive multifocal leukoencephalopathy (PML).
Observation:
- A multiple sclerosis patient on natalizumab developed symptoms suggestive of PML.
- Initial JC virus PCR in cerebrospinal fluid was negative, but a more sensitive quantitative PCR confirmed PML after 16 infusions.
- Immune reconstitution inflammatory syndrome (IRIS) occurred post-plasma exchange for natalizumab clearance.
Findings:
- Sensitive quantitative PCR is crucial for early PML diagnosis in natalizumab-treated patients.
- Plasma exchange can accelerate drug clearance.
- IRIS is a potential complication following treatment for natalizumab-associated PML.
Implications:
- This case highlights the importance of vigilant monitoring for PML in patients receiving natalizumab.
- Early and sensitive diagnostic methods are critical for timely intervention.
- Understanding IRIS is important for managing PML treatment complications.
More Related Videos
Related Concept Videos
Encephalitis l: Introduction
Multiple Sclerosis l: Introduction
Encephalitis ll: Pathophysiology
Cryptococcal Meningitis
Arboviral Encephalitis
Hepatic Encephalopathy

